Have any questions?
+44 1234 567 890
September 11, 2023
US Patent Office grants Patent for GQ Bio’s Lead Product
The United States Patent and Trademark Office grants patent covering GQ Bio’s lead gene therapy candidate GQ-501 for treatment of osteoarthritis.
The patent protects GQ Bio’s lead product candidate GQ-501 for treatment of osteoarthritis and its veterinary analogs. GQ-501 is a high-capacity gene therapy vector expressing proteoglycan 4 and interleukin-1 receptor antagonist currently in development for treatment of osteoarthritis.
Securing intellectual protection in the US, which is the largest osteoarthritis market, represents a major milestone for GQ Bio. The patent for this technology was already granted in 2020 in Europe, which is the second largest market.